Comprehensive evaluation of breast cancer immunotherapy and tumor microenvironment characterization based on interleukin genes-related risk model.

Sci Rep · 2022 · PMC9705306 · PMID 36443508

Europe PMC DOI

hedged sentence

0.0740

closest p · 1.5× alpha

0.0740

boldest claim

The sentences

did not reach statistical significancep = 0.074so close (0.05 < p ≤ 0.1)

According to the GSE194040 cohort, the pCR proportion of neoadjuvant chemotherapy (paclitaxel + pertuzumab + trastuzumab) in the high-risk group was significantly higher than that in the low-risk group, but it did not reach statistical significance (p = 0.074, Fig. 10 C), and twelve other neoadjuvant chemotherapy treatments were presented in Fig.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.